Frequency Therapeutics   Report issue

For profit Phase 2
Founded: Woburn MA United States (2015)

Organization Overview

First Clinical Trial
2017
NCT03300687
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Frequency Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (1)

fx-322 (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Deafness (Phase 2)

Hearing Loss (Phase 2)

Hearing Loss, Noise-Induced (Phase 2)

Hearing Loss, Sensorineural (Phase 2)

Hearing Loss, Sudden (Phase 1)

Presbycusis (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 1